Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Medicines register
Registers› Irish medicines ›Paliperidone Teva 150 mg prolonged-release suspension for injection
Medicines register · Ireland

Paliperidone Teva 150 mg prolonged-release suspension for injection

Authorisation PA0436/050/005 · Norton Waterford

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 19 Nov 2026
Licence holder
Norton Waterford (all products →)
Active substance
Paliperidone palmitate
Clinical trials
2 clinical trials →
Dosage form
Prolonged-release suspension for injection
Route of administration
Intramuscular use
ATC code
N05AX13
First authorised
03/12/2021
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Generic application (Article 10(1) of Directive No 2001/83/EC)

Paliperidone palmitate: supply and approvals

18 authorised products on the HPRA list contain Paliperidone palmitate. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 19 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 19 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 19 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 4 years (since 3 December 2021). The HPRA list marks it as marketed in Ireland.

Other medicines with Paliperidone palmitate in Ireland

17 other products on the HPRA list contain Paliperidone palmitate, from 4 licence holders; 2 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Paliperidone Teva 100 mg prolonged-release suspension for injectionNorton WaterfordNational authorisation (PA)Marketed
Paliperidone Teva 75 mg prolonged-release suspension for injectionNorton WaterfordNational authorisation (PA)Marketed
BYANNLI 1 000 mg prolonged-release suspension for injection in pre-filled syringeJanssen-Cilag International NVCentralised EU authorisationNot stated
BYANNLI 700 mg prolonged-release suspension for injection in pre-filled syringeJanssen-Cilag International NVCentralised EU authorisationNot stated
Paliperidone Clonmel 100 mg prolonged-release suspension for injection in pre-filled syringeClonmel Healthcare LtdNational authorisation (PA)Not marketed
Paliperidone Clonmel 150 mg prolonged-release suspension for injection in pre-filled syringeClonmel Healthcare LtdNational authorisation (PA)Not marketed
Paliperidone Clonmel 50 mg prolonged-release suspension for injection in pre-filled syringeClonmel Healthcare LtdNational authorisation (PA)Not marketed
Paliperidone Clonmel 75 mg prolonged-release suspension for injection in pre-filled syringeClonmel Healthcare LtdNational authorisation (PA)Not marketed
Paliperidone Teva 150 mg and Paliperidone Teva 100 mg prolonged-release suspension for injectionNorton WaterfordNational authorisation (PA)Not marketed
Paliperidone Teva 150 mg and Paliperidone Teva 100 mg prolonged-release suspension for injectionNorton WaterfordNational authorisation (PA)Not marketed
Paliperidone Teva 25 mg prolonged-release suspension for injectionNorton WaterfordNational authorisation (PA)Not marketed
Paliperidone Teva 50 mg prolonged-release suspension for injectionNorton WaterfordNational authorisation (PA)Not marketed

All 18 products with Paliperidone palmitate →

The licence holder

Norton Waterford holds 37 products on the HPRA list, with 20 different active substances; 23 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 20 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.